NCT05292664 2026-03-12
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Phase 1 Recruiting
Clinical Trials
63 trialsNCT07070466 2026-03-06
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Massachusetts General Hospital
Phase 2 Recruiting
NCT04230187 2026-03-05
TRIBE-C
Sun Yat-sen University
Phase 3 Recruiting
NCT04683315 2026-03-05
PANCREAS
Medical College of Wisconsin
Phase 2 Recruiting
NCT05677490 2026-03-04
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT04215731 2026-03-03
FOBEAR
Sun Yat-sen University
Phase 3 Recruiting
NCT06835387 2026-02-17
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06109467 2026-02-09
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05412082 2026-02-06
SMART TNT
University of Miami
Phase 1 Recruiting
NCT07214298 2026-02-06
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT04495088 2026-02-02
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
Universitätsmedizin Mannheim
Phase 3 Recruiting
NCT06958328 2026-02-02
LAP100
NRG Oncology
Phase 3 Recruiting
NCT06381154 2026-01-30
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Recruiting
NCT03801876 2026-01-14
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NRG Oncology
Phase 3 Recruiting
NCT03322995 2026-01-08
PANC
Medical College of Wisconsin
Phase 2 Recruiting
NCT05802056 2025-12-19
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Mayo Clinic
Phase 1 Recruiting
NCT05959356 2025-12-17
CEIL
Sun Yat-sen University
Phase 2 Recruiting
NCT05008809 2025-12-12
AIO-KRK-0418
Charite University, Berlin, Germany
Phase 3 Recruiting
NCT06733038 2025-12-08
AtezoTRIBE2
Gruppo Oncologico del Nord-Ovest
Phase 3 Recruiting
NCT06941857 2025-12-03
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT04703101 2025-11-10
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT03800693 2025-11-06
2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
Emory University
Phase 2 Recruiting
NCT04615013 2025-10-30
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06576037 2025-10-15
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07204574 2025-10-02
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Chang Gung Memorial Hospital
Phase 1/2 Recruiting
NCT04361708 2025-10-01
I-FLOAT
University of Chicago
Phase 1 Recruiting
NCT06253611 2025-09-22
BIG
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT07183865 2025-09-19
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
Fudan University
Phase 2 Recruiting
NCT06490536 2025-08-29
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3 Recruiting
NCT07018570 2025-08-26
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting
NCT06867822 2025-08-24
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
University of Alabama at Birmingham
Phase 1 Recruiting
NCT05571644 2025-07-23
OPTICAL-2
Sun Yat-sen University
Phase 2 Recruiting
NCT06719362 2025-07-10
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Providence Health & Services
Phase 1 Recruiting
NCT02885753 2025-07-09
OSCAR
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT06780787 2025-06-26
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
City of Hope Medical Center
Phase 2 Recruiting
NCT07025174 2025-06-17
SAIB
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT02366819 2025-06-13
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
Phase 4 Recruiting
NCT05727163 2025-05-30
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Sun Yat-sen University
Phase 2 Recruiting
NCT05870800 2025-05-25
NICER
Baylor College of Medicine
Phase 2 Recruiting
NCT06741020 2025-05-23
HAICI
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT05624138 2025-05-11
The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy
Tanta University
Phase 3 Recruiting
NCT06438822 2025-05-07
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
West China Hospital
Phase 2 Recruiting
NCT06028737 2025-05-06
OCTASUR
Ukrainian Society of Clinical Oncology
Phase 2/3 Recruiting
NCT06483555 2025-04-16
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04460352 2025-03-06
NEEDS
Karolinska University Hospital
Phase 3 Recruiting
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT04447352 2024-11-12
PREVENT
Krankenhaus Nordwest
Phase 3 Recruiting
NCT05628038 2024-10-01
TORCH-R
Fudan University
Phase 2 Recruiting
NCT04927780 2024-08-28
PREOPANC-3
Erasmus Medical Center
Phase 3 Recruiting